Therefore, we examined the therapeutic targeting of Sema3C by intravenous injection of rAAV8-shSema3C alone or in combination with sorafenib in a DEN+CCl4-induced HCC mouse model. Here, SEMA3C is linked to hepatocellular carcinoma.